Hormone-resistant Prostate Cancer

CLINICAL_TRIALS research · 2025-12-05

Clinical Trial Update: Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer [NA]

A clinical trial is studying whether a controlled low-calorie diet can reduce chemotherapy side effects and improve treatment response in pa…

CLINICAL_TRIALS trial_result · 2023-05-01

Clinical Trial Update: Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer [Phase 2]

Phase 2 clinical trial update for trametinib in progressive metastatic hormone-resistant prostate cancer; currently active but not recruitin…

CLINICAL_TRIALS trial_result · 2022-08-08

Clinical Trial Update: Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer [Phase 2]

Phase 2 trial evaluating docetaxel with or without ascorbic acid in metastatic, hormone-resistant prostate cancer has terminated; results po…

CLINICAL_TRIALS trial_result · 2022-07-13

Clinical Trial Update: Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer [Phase 1, Phase 2]

Phase 1/2 trial evaluating enzalutamide with mifepristone in metastatic hormone-resistant prostate cancer completed with results posted in 2…

CLINICAL_TRIALS trial_result · 2021-08-05

Clinical Trial Update: Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies [Phase 2]

Phase 2 trial evaluating docetaxel and carboplatin in metastatic castration-resistant prostate cancer with DNA-repair deficiencies was termi…

CLINICAL_TRIALS trial_result · 2021-05-14

Clinical Trial Update: Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 2]

Phase 2 trial update for abiraterone acetate in metastatic hormone-resistant prostate cancer has completed with posted results.

CLINICAL_TRIALS trial_result · 2021-03-25

Clinical Trial Update: Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 1, Phase 2]

Phase 1/2 clinical trial evaluating docetaxel, prednisone, and pasireotide in metastatic hormone-resistant prostate cancer has completed wit…

CLINICAL_TRIALS trial_result · 2021-03-23

Clinical Trial Update: Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer [NA]

Completed clinical trial evaluating cabozantinib-s-malate in hormone-resistant metastatic prostate cancer; results posted in 2021.

CLINICAL_TRIALS trial_result · 2021-01-25

Clinical Trial Update: Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 2]

Phase 2 trial evaluating cabazitaxel plus prednisone in metastatic hormone-resistant prostate cancer was terminated; results posted in 2021.

CLINICAL_TRIALS trial_result · 2020-08-25

Clinical Trial Update: Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer [Phase 2]

Phase 2 trial assessing sipuleucel-T with or without radiation therapy in hormone-resistant metastatic prostate cancer has completed with re…

CLINICAL_TRIALS trial_result · 2019-06-17

Clinical Trial Update: Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer [Phase 1, Phase 2]

Phase 1/2 trial evaluating cixutumumab plus temsirolimus in metastatic prostate cancer has completed with posted results.

CLINICAL_TRIALS trial_result · 2018-09-12

Clinical Trial Update: Tivantinib in Treating Patients With Metastatic Prostate Cancer [Phase 2]

Phase 2 clinical trial update for tivantinib in metastatic prostate cancer has completed with results posted in 2018.

CLINICAL_TRIALS trial_result · 2018-05-25

Clinical Trial Update: Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer [Phase 2]

Phase 2 trial of dasatinib (Sprycel) in hormone-refractory prostate cancer completed; results posted in 2018.

CLINICAL_TRIALS trial_result · 2018-05-18

Clinical Trial Update: Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 2]

Phase 2 clinical trial evaluating ipilimumab in combination with androgen suppression therapy for metastatic hormone-resistant prostate canc…

CLINICAL_TRIALS trial_result · 2017-12-11

Clinical Trial Update: Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel [Phase 2]

Phase 2 trial evaluating phenelzine sulfate with docetaxel in hormone-resistant/metastatic prostate cancer after first-line docetaxel; study…

CLINICAL_TRIALS trial_result · 2016-05-20

Clinical Trial Update: Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 2]

Phase 2 trial evaluating sipuleucel-T with or without tasquinimod in metastatic hormone-resistant prostate cancer has completed, with result…

CLINICAL_TRIALS trial_result · 2015-04-14

Clinical Trial Update: Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy [Phase 2]

Phase 2 clinical trial update for STA-9090 (an Hsp90 inhibitor) in metastatic hormone-resistant prostate cancer after docetaxel therapy; com…

CLINICAL_TRIALS trial_result · 2014-07-23

Clinical Trial Update: Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 2]

Phase 2 trial evaluating docetaxel and prednisone with or without vaccine therapy in metastatic hormone-resistant prostate cancer; the study…

CLINICAL_TRIALS trial_result · 2013-06-05

Clinical Trial Update: Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer [Phase 2]

Phase 2 trial evaluated combination chemotherapy plus bevacizumab for metastatic prostate cancer and has completed.

Top drugs studied for this disease